atossagenetics.comAtossa Therapeutics - A Clinical-Stage Biopharmaceutical Company

Vision Investors Culture About Development Pipeline Clinical Trials Contact Us Search for: Creating innovative therapies and novel delivery methods Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19. About Atossa Contact Us COVID-19 Programs Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus. Transforming the Breast Cancer Paradigm Endoxifen We are developing the promise of endoxifen and exploiting its potential to both help prevent as well as to treat breast cancer with our proprietary Topical and Oral Endoxifen. Microcatheters We are developing proprietary intraductal microcatheter technology for the potential delivery of drugs and immunotherapies (such as CAR-T) through the breast ducts directly to the site of the cancer. Learn More Advancing Our Programs We are advancing programs to help develop treatments that are effective and affordable. View Product Pipeline Advancing Our Programs We are advancing programs to help develop treatments that are effective and affordable. View Product Pipeline Developing Solutions to Address all Sections of the Breast Cancer Paradigm Prevention Window Window-of-Opportunity (Pre-surgery) Refractory (Post-surgery) Gynecomastia Learn More A Global Effort We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner. READ OUR STORY -- A Global Effort -- We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner. READ OUR STORY In the News Sep 1, 2020 Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19 Aug 26, 2020 Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020 Aug 17, 2020 Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19 read all news Presentations Legal Sitemap Copyright © 2020 Atossa Therapeutics, Inc. All Rights Reserved. Open Large Modal -- Join us ... in our mission to prevent breast cancer [mailpoet_form id="2"] Each and every email signup helps us fight the good fight . We respect your email privacy. Unsubscribe any time. Close Font Resize A- A+ Keyboard navigation Readable Font Underline links Highlight Links Clear cookies Invert Colors Close About Us Articles Breast Cancer Awareness Month Clinical Trials Contact Us Contact Us Old Culture Development Pipeline Home Investors Legal Legal Notice Privacy Policy Sitemap Subscription Confirmed Test1 Unsubscribe Vision We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok...